Ambrosia Bio Ltd

Based in Jerusalem, Israel, and founded by Ziv Zwighaft in 2020, Ambrosia Bio Ltd operates as a biotechnology company offering an enzyme-based technology for allulose. In June 2023, the firm raised its seed funding. The company offers healthier alternatives to sugar called Allulose, a low-glycemic, low-calorie, non-cariogenic sweetener or rare sugar. Allulose has similar taste technical and textural profiles and sweetness to sugar but without the aftertaste often associated with artificial sweeteners.

Ambrosia develops technology and processes such as plug-and-play, three-pronged enzyme-based process solutions to convert industrial sugars into minimal-calorie rare sugars. The firm’s technology is available to 600 sugar producers worldwide, as of June 2023. Ambrosia Bio has also partnered with organizations such as Ginkgo Bioworks and Novasep PS to leverage their expertise in enzymes, process engineering, and industrial infrastructure. The company plans to utilize its June 2023 funding to produce samples, build its IP, and sign commercial agreements.